SYSTEMS GENETICS TO DETERMINE RISK OF DEVELOPING DIABETES COMPLICATIONS
Emeritus Professor Grant Morahan, Professor of Diabetes Research, University of Western Australia Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research), Perth, Australia & Honorary Professor, Baker Department of Cardiometabolic Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | December 2025
Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.
As a member of the Steering Committee of the Type 1 Diabetes Genetics Consortium, he worked to design the global study recruiting and characterising T1D genetics, which resulted in identification of over 40 T1D risk genes. The culmination of this program, for which Prof Morahan was PI of the Asia-Pacific Network, was published in Nature Genetics (41:703-707) and has been cited 1579 times.
Currently, he is a member of the Steering Committee of the Environmental Determinants of Islet Autoimmunity (ENDIA) Study, the only study in the world investigating T1D families to follow at-risk babies from pregnancy through childhood. Completing recruitment in 2020, the study already has 40 publications.
His latest discovery involves next-generation algorithms that are able to predict whether a person will be genetically high/low risk of developing a number of complex genetic diseases. Professor Morahan is working toward commercialising these genetic tests so they can benefit the public and the healthcare system.
During his career, Prof Morahan has supervised 23 postgraduate students and mentored nine postdoctoral positions. Since 2003, Prof Morahan has applied for and received close to $20 million in research funds, both nationally and internationally. He has 299 academic publications, 17,0744 citations and has an h-index of 60.
Source: Supplied
https://orcid.org/0000-0002-8562-7325
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
In his father’s footsteps as a kidney transplant specialist
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
